Rexigo 120mg Tablet

• Treat prostate cancer

Some medicines show side effects but it depends from person to person and based on the patient response to the treatment. Rexigo 120mg also causes various symptoms but they can be manageable with treatments. Common ones include:

• Tiredness
• Constipation
• Diarrhea
• Dizziness
• Headache
• Nausea
• Rash
• Fatigue
• low red cell count (anemia)
• Breast enlargement in men (gynecomastia)
• Hot flushes
• Increased blood sugar levels
• Increased blood fat (triglyceride) levels
• Muscle and joint pain
• Decreased blood hemoglobin levels
• Increased liver enzymes​

• Rexigo 120mg tablet should be taken with or without food, exactly as prescribed by healthcare professional. Take it at the same time everyday to enhance the effectiveness of the treatment.
• Do not crush, crew or break the tablet just swallow it whole with a glass of water. Proper medication dosage and duration is correctly administered by the healthcare professional to ensure safe and effective treatment.
  

• Rexigo 120mg tablet works by lowering the amount of testosterone hormone which is responsible for the production of cancer cells in the body. In this way, it slows or stops the spreading of cancer cells to other parts of the body.
• It acts by directly blocking gonadotropin releasing hormone (GnRH) receptors in the pituitary gland which reduces the release of luteinizing hormone and ultimately suppresses testosterone production. It helps control tumor growth without causing an initial rise in testosterone level.
  

• Shore, N. D., Saad, F., Cookson, M. S., George, D. J., Saltzstein, D. R., Tutrone, R., ... & Tombal, B. (2020). Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. New England Journal of Medicine, 382(23), 2187-2196. https://pubmed.ncbi.nlm.nih.gov/32469183/
  
• Shirley, M. (2023). Relugolix: a review in advanced prostate cancer. Targeted Oncology, 18(2), 295-302. https://pubmed.ncbi.nlm.nih.gov/36652173/
  
• Spratt, D. E., George, D. J., Shore, N. D., Cookson, M. S., Saltzstein, D. R., Tutrone, R., ... & Tombal, B. F. (2024). Efficacy and safety of radiotherapy plus relugolix in men with localized or advanced prostate cancer. JAMA oncology, 10(5), 594-602. https://pubmed.ncbi.nlm.nih.gov/38451492/
  
• Al-Hendy, A., Lukes, A. S., Poindexter III, A. N., Venturella, R., Villarroel, C., Critchley, H. O., ... & Stewart, E. A. (2021). Treatment of uterine fibroid symptoms with relugolix combination therapy. New England Journal of Medicine, 384(7), 630-642. https://pubmed.ncbi.nlm.nih.gov/33596357/
  
• Giudice, L. C., As-Sanie, S., Ferreira, J. C. A., Becker, C. M., Abrao, M. S., Lessey, B. A., ... & Johnson, N. P. (2022). Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). The Lancet, 399(10343), 2267-2279. https://pubmed.ncbi.nlm.nih.gov/35717987/